Form 4: Myriad Genetics Director Mark Davis Granted Over 24,000 Restricted Stock Units

Myriad Genetics Inc. Director Mark Steven Davis was granted 24,148 restricted stock units of common stock on June 5, 2025, increasing his direct beneficial ownership to 46,964 shares.

Summary

• Mark Steven Davis, a Director of Myriad Genetics Inc. (MYGN), was granted 24,148 shares of common stock on June 5, 2025.
• These shares were granted as restricted stock units (RSUs) under the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock, with a grant price of $0.
• The RSUs will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.
• Following this transaction, Mr. Davis directly beneficially owns a total of 46,964 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal as it aligns management's interests with shareholders, though it's a routine compensation event rather than a significant strategic announcement.

Positives

• The grant of 24,148 restricted stock units to Director Mark Steven Davis aligns his interests more closely with those of shareholders, as his compensation is tied to the company's future performance.
• The transaction demonstrates the company's commitment to its equity incentive plan for directors, which is a common practice for attracting and retaining qualified board members.

Negatives

• No specific negative financial or operational impacts are indicated in this Form 4 filing, as it primarily reports an equity grant.

Risks

• The document does not explicitly mention any new or existing risks to the company's operations or financial health.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the vesting schedule of the granted restricted stock units.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries, and does not provide specific insights into broader industry trends within the genetics or healthcare sectors.

Related Party Transactions

• The grant of restricted stock units to Mark Steven Davis, a Director of Myriad Genetics, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of equity to a director can be viewed positively as it aligns the director's financial interests with those of shareholders, potentially incentivizing long-term value creation. However, it also represents dilution if new shares are issued, or a cost if shares are repurchased for the plan.
• Employees: The transaction does not directly impact general employees, though it is part of a broader equity incentive plan that may also benefit other employees.

Next Steps

• The granted restricted stock units will vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following the grant.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Beneficial Ownership, SEC Filing